IN2015DN01361A - - Google Patents
Info
- Publication number
- IN2015DN01361A IN2015DN01361A IN1361DEN2015A IN2015DN01361A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A IN 1361DEN2015 A IN1361DEN2015 A IN 1361DEN2015A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- fusion proteins
- constant regions
- incorporating
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides constant regions incorporating a cysteine mutation and linked to a µ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and µ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes e.g. pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G which facilitates purification and may exhibit pH dependent FcRn binding which is associated with a relatively long in vivo half life. Depending on the isotype and subtype the nature of the antigen and presence of an additional IgG hinge domain such antibodies or fusion proteins may also have properties of specific binding to protein A and effector functions such as ADCC, CDC and opsonization.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679045P | 2012-08-02 | 2012-08-02 | |
| US201361767724P | 2013-02-21 | 2013-02-21 | |
| PCT/US2013/053086 WO2014022592A1 (en) | 2012-08-02 | 2013-07-31 | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01361A true IN2015DN01361A (en) | 2015-07-03 |
Family
ID=50025683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1361DEN2015 IN2015DN01361A (en) | 2012-08-02 | 2013-07-31 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9540442B2 (en) |
| EP (1) | EP2880057A4 (en) |
| JP (1) | JP2015524821A (en) |
| CN (1) | CN104684928A (en) |
| CA (1) | CA2879814A1 (en) |
| IN (1) | IN2015DN01361A (en) |
| WO (1) | WO2014022592A1 (en) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| WO2009018122A2 (en) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the cns |
| ES2725200T3 (en) | 2009-10-09 | 2019-09-20 | Armagen Inc | Methods and compositions to increase the activity of iduronate 2-sulfatase in the CNS |
| US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| MX2019001355A (en) | 2012-05-10 | 2023-01-17 | Bioatla Llc | Multi-specific monoclonal antibodies. |
| WO2014022592A1 (en) | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| CA2939201A1 (en) * | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
| KR20160130463A (en) | 2014-03-05 | 2016-11-11 | 유씨비 바이오파마 에스피알엘 | Multimeric fc proteins |
| PL3560954T3 (en) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Modified j-chain |
| AU2015266958A1 (en) | 2014-05-28 | 2016-12-08 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
| MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| CA2970385C (en) * | 2014-12-19 | 2023-04-04 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex and use thereof |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| SG11201705116SA (en) * | 2015-01-20 | 2017-08-30 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| ES2874558T3 (en) * | 2015-03-04 | 2021-11-05 | Igm Biosciences Inc | CD20-binding molecules and their uses |
| JP6882184B2 (en) * | 2015-03-25 | 2021-06-02 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multivalent hepatitis B virus antigen-binding molecule and its use |
| JP6955445B2 (en) * | 2015-04-07 | 2021-10-27 | ジェネンテック， インコーポレイテッド | Antigen binding complex with agonistic activity and how to use it |
| AU2016249404B2 (en) * | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| CA2999284C (en) | 2015-09-30 | 2023-06-13 | Igm Biosciences A/S | Binding molecules with modified j-chain |
| DK3356401T3 (en) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | BINDING MOLECULES WITH MODIFIED J-CHAIN |
| KR20180069066A (en) | 2015-10-30 | 2018-06-22 | 갤럭시 바이오테크, 엘엘씨 | Extremely powerful antibodies that bind to death receptor 4 and death receptor 5 |
| TWI637966B (en) * | 2015-11-30 | 2018-10-11 | 輝瑞股份有限公司 | Antibodies and antibody fragments for site-specific conjugation |
| TWI778491B (en) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
| CN108883173B (en) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | Antibodies and methods of use thereof |
| EP3402507A4 (en) * | 2016-01-11 | 2019-08-07 | Inhibrx, Inc. | Multivalent and multispecific ox40-binding fusion proteins |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| CN109311949B (en) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | Method for storing separation matrices |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| EP3455241B1 (en) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Method of cleaning and/or sanitizing a separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194597A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| EP3496536A4 (en) * | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| EP3487298A4 (en) * | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| MA46770A (en) | 2016-11-09 | 2019-09-18 | Agenus Inc | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| KR20200064096A (en) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | Antibodies, activatable antibodies, bispecific antibodies and bispecific activatable antibodies and methods of using them |
| US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| KR102232659B1 (en) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | polypepide for delivery of antigen, Fc-fusion protein comprising thereof and use thereof |
| BR112021002164A2 (en) | 2018-08-13 | 2021-08-03 | Inhibrx, Inc. | ox40-binding polypeptides and uses thereof |
| EP3902564A4 (en) * | 2018-12-27 | 2022-09-28 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
| SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
| SG11202109033XA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| CN114127113A (en) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | Multifunctional molecules binding to calreticulin and uses thereof |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CA3130508A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
| CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074144A (en) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | Antibody molecules that bind to NKp30 and uses thereof |
| KR20220029343A (en) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | Hexameric anti-VEGF antibody, and compositions comprising the same |
| EP4206226A1 (en) | 2020-08-31 | 2023-07-05 | Medytox Inc. | Anti-vegf hexameric antibody and composition comprising same |
| GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
| CN115724985A (en) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | CDC platform antibody |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147326A1 (en) | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| US6475749B1 (en) | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| CN101124245A (en) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| US20100297103A1 (en) * | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| GB0922209D0 (en) * | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| US8952134B2 (en) * | 2011-09-26 | 2015-02-10 | Jn Biosciences Llc | Hybrid constant regions |
| WO2014022592A1 (en) | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
-
2013
- 2013-07-31 WO PCT/US2013/053086 patent/WO2014022592A1/en active Application Filing
- 2013-07-31 IN IN1361DEN2015 patent/IN2015DN01361A/en unknown
- 2013-07-31 CN CN201380041074.3A patent/CN104684928A/en active Pending
- 2013-07-31 EP EP13825409.9A patent/EP2880057A4/en not_active Withdrawn
- 2013-07-31 CA CA2879814A patent/CA2879814A1/en active Pending
- 2013-07-31 US US13/956,121 patent/US9540442B2/en active Active
- 2013-07-31 JP JP2015525568A patent/JP2015524821A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2880057A1 (en) | 2015-06-10 |
| JP2015524821A (en) | 2015-08-27 |
| WO2014022592A1 (en) | 2014-02-06 |
| CA2879814A1 (en) | 2014-02-06 |
| EP2880057A4 (en) | 2016-03-23 |
| CN104684928A (en) | 2015-06-03 |
| US20140037621A1 (en) | 2014-02-06 |
| US9540442B2 (en) | 2017-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01361A (en) | ||
| MX2010006767A (en) | Hepatitis c virus antibodies. | |
| CY1120414T1 (en) | ANTIBODIES CONNECTED TO NO40 AND THEIR USES | |
| CA2849765C (en) | Hybrid constant regions | |
| CY1120412T1 (en) | ILL-31 SPECIALIZED PARTICULAR PARTS | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| WO2016081746A8 (en) | Antibodies comprising modified heavy constant regions | |
| NZ706232A (en) | Anti-cd3 antibodies and uses thereof | |
| EA201390923A1 (en) | MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD | |
| IN2014MN00873A (en) | ||
| AR084210A1 (en) | PROTEINS OF UNION TO TNF-a | |
| NZ600262A (en) | Anti-her3 antibodies and uses thereof | |
| DK2681244T3 (en) | CEA ANTIBODIES | |
| MX342413B (en) | Antibodies to matrix metalloproteinase 9. | |
| NZ578844A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| MX2018007630A (en) | Antibodies to matrix metalloproteinase 9. | |
| NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| EA201591407A1 (en) | ANTIBODIES CONTAINING CHEMICAL CONSTANT DOMAINS | |
| NZ591056A (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
| NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
| EA201490745A1 (en) | POLYPEPTIDES OF ANTIBODIES THAT CAUSE ANTAGONISM CD40L | |
| UA106070C2 (en) | Antibody that specifically binds to egfr and her3 | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 |